Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer

British Journal of Cancer, Published online: 11 May 2020; doi:10.1038/s41416-020-0865-zAscites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

National advocacy group Black Women for Wellness joined more than 170 other nonprofits from 51 countries last week in demanding that Johnson &Johnson stop the worldwide distribution of its iconic Johnson’s Baby Powder. The demand for a global distribution ban stems from the potential for asbestos in talc, which has led to various cancers and thousands of personal injury lawsuits. A majority of talc cases pertain to women and ovarian cancer. A small percentage of the legal claims involve mesothelioma, a rare and aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Johnson &John...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: Secondary cytoreduction remains a viable treatment option for select patients for now, but this is entirely dependent on the highly anticipated overall survival results of DESKTOP III and SOC 1. PMID: 32649655 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Authors: O'Malley D PMID: 32649652 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Abstract BACKGROUND: Up to 70% of the patients with advanced ovarian cancer have a relapse after primary therapy. New agents and approaches are urgently needed to avoid or slow down the reccurence. OBJECTIVES: To investigate the efficacy of PARP inhibitors (PARPis) as maintenance treatment in patients with newly diagnosed advanced ovarian cancer. SEARCH STRATEGY: PubMed, Medline, Embase, Cochrane Library and Web of Science databases. SELECTION CRITERIA: All randomized clinical trials (RCTs) that compared PARPis and placebo as first-line maintenance therapy in ovarian cancer. DATA COLLECTION AND...
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research
Lung cancer is the second most common cancer in the United States with a 5-year relative survival rate of only 18 % [1]. A widely used non-small cell lung cancer (NSCLC) chemotherapy treatment is gemcitabine in combination with carboplatin which is also used in the treatment of other solid tumors such as bladder, ovarian and breast cancer. Gemcitabine/carboplatin treatment is known to cause severe toxicity that can lead to the need for postponed treatment, reduced doses and in some cases even discontinuation of treatment [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Publication date: Available online 11 July 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Nikita Naredi, Pankaj Talwar, Sandeep Karunakaran
Source: Medical Journal Armed Forces India - Category: General Medicine Source Type: research
Authors: Grandi G, Caroli M, Cortesi L, Toss A, Tazzioli G, Facchinetti F Abstract INTRODUCTION: Risk-reducing-salpingo-oophorectomy (RRSO) inevitably leads BRCA mutation carriers to premature menopause. AREAS COVERED: To evaluate the existing evidence for use of postmenopausal hormone therapy (HT) in BRCAmc, after RRSO or menopause occurring naturally, for both breast cancer (BC) survivors and those without BC. EXPERT OPINION: All BC survivors are excluded from any HT treatment: in other BRCAmc, before 51 years of age the benefits of HT overcome the risks after RRSO and/or premature ovarian insufficie...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
ConclusionOur results reveal that affected children with the novel pathogenetic mutations p.C242R and p.S445* in theMCM8 gene are characterized by POI, short stature, cancer susceptibility, and genomic instability.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Ovarian Cancer | Ovaries | UK Health